Targeting lysosomal pH restores mitochondrial quality control in GBA1 -mutant Parkinson’s disease

Sheshadri, Preethi, Costa-Besada, Maria Alicia, Fisher, Alessia, Kiraly, Szilvia, Singh, Kritarth, Kourouzidou, Ioanna, Blacker, Thomas S., Zeng, Jialiu, Shirihai, Orian S., Grinstaff, Mark W. and Duchen, Michael R. 2026. Targeting lysosomal pH restores mitochondrial quality control in GBA1 -mutant Parkinson’s disease. Translational Neurodegeneration 15 (1) , 27. 10.1186/s40035-026-00559-z

	PDF - Supplemental Material Download (2MB)
	PDF - Published Version Download (12MB)
	PDF - Supplemental Material Download (3MB)

Abstract

Background: Heterozygous mutations in the glucocerebrosidase gene (GBA1), which encodes the lysosomal enzyme β-glucocerebrosidase (GCase), are a genetic risk factor for Parkinson’s disease (PD). The pathophysiological consequences of GBA1 mutations on dopaminergic neuronal function, especially their impact on lysosomal function, mitophagy, and mitochondrial bioenergetics, remain unclear. Methods: Fibroblasts and dopaminergic neurons generated from induced pluripotent stem cells (iPSCs) derived from patients with GBA1-PD were used in the study. Live-cell imaging was performed to measure lysosomal acidification, protease activity, mitochondrial membrane potential, and mitophagy. Mitochondrial morphology and autophagic vesicles were examined using transmission electron microscopy. Oxygen consumption rate was measured by Seahorse assay. V-ATPase assembly was quantified using fluorescence lifetime imaging with Förster resonance energy transfer (FLIM-FRET), and pharmacological interventions included rapamycin and acidic nanoparticles. Results: GCase activity, lysosomal acidification, protease activity, mitophagy and mitochondrial bioenergetic function were all impaired in GBA1 mutant dopaminergic neurons. Mitochondria were fragmented, with reduced membrane potential and oxygen consumption. Mechanistic target of rapamycin complex 1 (MTORC1) was constitutively phosphorylated and FLIM-FRET measurements confirmed impairment of lysosomal V-ATPase assembly, which was reversed by rapamycin treatment. Rapamycin and lysosome-targeting acidic nanoparticles rescued lysosomal pH and restored mitophagy, mitochondrial membrane potential and mitochondrial oxidative phosphorylation complex level in the GBA1 mutant dopaminergic neurons. Conclusions: We revealed a novel mechanistic link between GBA1 mutations and mitochondrial dysfunction, as the disruption of V-ATPase assembly driven by MTORC1 activation impairs lysosomal acidification. This causes impairment of mitophagy, leading to mitochondrial dysfunction, undermining dopaminergic cell function and fate. Pharmacological intervention with rapamycin or acidic nanoparticles restores lysosomal pH and rescue mitochondrial function, representing a novel therapeutic approach for GBA1-PD .

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Schools > Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/, Type: open-access
Publisher:	BioMed Central
Date of First Compliant Deposit:	22 June 2026
Date of Acceptance:	6 May 2026
Last Modified:	22 Jun 2026 16:30
URI:	https://orca.cardiff.ac.uk/id/eprint/187698

Actions (repository staff only)

Edit Item